Ethos recommends support for Actelion Board at the Company's AGM
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Ethos recommends support for Actelion Board at the Company's AGM
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leading Swiss proxy adviser opposes proposals placed by Elliott
ALLSCHWIL/BASEL, SWITZERLAND - 19 April 2011 - Actelion Ltd (SIX: ATLN)
announced today that Ethos, the Swiss Foundation for Sustainable Development,
currently composed of 113 institutional investors, has confirmed that it will
recommend its members to vote for the proposals put forward by Actelion's Board
at the Company's Annual General Meeting (AGM) on 5 May 2011. Ethos recommends
voting in favor of all proposals of Actelion including the composition of the
Board of Directors and to reject Elliott's proposals. As a general policy Ethos
supports the introduction of a one-year term of office for directors.
Robert E. Cawthorn, Chairman of Actelion, said: "We are pleased that another
independent proxy advisor recommends voting for the proposals Actelion has
brought forward. After most recent supportive statements from BB Biotech and
IVOX, Ethos' statement is again an important signal to our shareholders. We
firmly believe that voting for all of Actelion's proposals is in the best
interest of all shareholders."
Ethos published the following statement today: "Ethos supports the strategy of
Actelion's Board allowing its shareholders to fully benefit from the potential
of Macitentan, Actelion's new drug intending to replace Tracleer, Actelion's
blockbuster whose patent expires in 2015. Via its different resolutions, Elliott
seems to favour the sale of Actelion. In the long term interests of all the
company's stakeholders, Ethos recommends that shareholders oppose the
resolutions of the hedge fund and that they support the board of directors by
not appointing any of Elliott's candidates."
Actelion encourages all shareholders to register their shares no later than 28
April 2011 and to follow the Board's recommendations by voting FOR all of
Actelion's experienced director nominees and proposals - either by attending the
AGM on 5 May 2011 in person or by filling out and returning the independent
proxy card.
More information on how to register and vote your shares is available on
Actelion's website at: http://www.actelion.com/en/investors/first-time-
investor/how-to-register-shares.page
If you need assistance with voting your shares, please call D.F. King & Co.,
Inc. toll free from North America at + 1 800 967 7635, or toll free from
Continental Europe at 00800 5464 5464.
###
Note to Editors
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1507832/442730.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1507832]
Unternehmensinformation / Kurzprofil:
Datum: 19.04.2011 - 17:35 Uhr
Sprache: Deutsch
News-ID 53724
Anzahl Zeichen: 6822
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ethos recommends support for Actelion Board at the Company's AGM"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
